The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Orally administrative melk (maternal embryonic leucine zipper kinase)-targeting small molecule inhibitor suppresses the growth of various types of human cancer.
Suyoun Chung
No relevant relationships to disclose
Hanae Suzuki
Employment or Leadership Position - OncoTherapy Science
Takashi Miyamoto
Employment or Leadership Position - OncoTherapy Science
Naofumi Takamatsu
Employment or Leadership Position - OncoTherapy Science
Ayako Tatsuguchi
No relevant relationships to disclose
Koji Ueda
No relevant relationships to disclose
Kyoko Kijima
Employment or Leadership Position - OncoTherapy Science
Yo Matsuo
Employment or Leadership Position - OncoTherapy Science
Yusuke Nakamura
Consultant or Advisory Role - OncoTherapy Science
Stock Ownership - OncoTherapy Science
Research Funding - OncoTherapy Science